21 related articles for article (PubMed ID: 38570712)
1. CKS1B as a potential target for prognostic assessment and intervention in pancreatic cancer and its role in abnormal proliferation and cellular phenotype through mediation of cell cycle signaling pathways.
Tang Y; Lan X; Yan M; Fu Z; Li H
Saudi Med J; 2024 Feb; 45(2):128-138. PubMed ID: 38309745
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
3. PKMYT1 inhibits lung adenocarcinoma progression by abrogating AKT1 activity.
Wang S; Liu X; Zhou T; Li J; Lin Y; Zhou A; Huang J; Zhao J; Cai J; Cai X; Huang Y; Li X
Cell Oncol (Dordr); 2023 Feb; 46(1):195-209. PubMed ID: 36350496
[TBL] [Abstract][Full Text] [Related]
4. ELF3 promotes gemcitabine resistance through PKMYT1/CDK1 signaling pathway in gallbladder cancer.
Yang L; Wang H; Guo M; He M; Zhang W; Zhan M; Liu Y
Cell Oncol (Dordr); 2023 Aug; 46(4):1085-1095. PubMed ID: 36988891
[TBL] [Abstract][Full Text] [Related]
5. Identification of GRIN2D as a novel therapeutic target in pancreatic ductal adenocarcinoma.
Wang J; Wong CH; Zhu Y; Yao X; Ng KKC; Zhou C; To KF; Chen Y
Biomark Res; 2023 Aug; 11(1):74. PubMed ID: 37553583
[TBL] [Abstract][Full Text] [Related]
6. Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition.
Ramaker RC; Hardigan AA; Gordon ER; Wright CA; Myers RM; Cooper SJ
BMC Cancer; 2021 May; 21(1):632. PubMed ID: 34049503
[TBL] [Abstract][Full Text] [Related]
7. Cyclin Dependent Kinase-1 (CDK-1) Inhibition as a Novel Therapeutic Strategy against Pancreatic Ductal Adenocarcinoma (PDAC).
Wijnen R; Pecoraro C; Carbone D; Fiuji H; Avan A; Peters GJ; Giovannetti E; Diana P
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503199
[TBL] [Abstract][Full Text] [Related]
8. DNA Damage Repair Deficiency in Pancreatic Ductal Adenocarcinoma: Preclinical Models and Clinical Perspectives.
Stoof J; Harrold E; Mariottino S; Lowery MA; Walsh N
Front Cell Dev Biol; 2021; 9():749490. PubMed ID: 34712667
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide CRISPR screens identify PKMYT1 as a therapeutic target in pancreatic ductal adenocarcinoma.
Wang S; Xiong Y; Luo Y; Shen Y; Zhang F; Lan H; Pang Y; Wang X; Li X; Zheng X; Lu X; Liu X; Cheng Y; Wu T; Dong Y; Lu Y; Cui J; Jia X; Yang S; Wang L; Wang Y
EMBO Mol Med; 2024 May; 16(5):1115-1142. PubMed ID: 38570712
[TBL] [Abstract][Full Text] [Related]
10. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
